Australian Medical Doctor/Bioethicist Reveals Huge Profits are Motive Behind Cloning Push

TORONTO, October 29, 2004 (LifeSiteNews.com) – Embryonic stem cell therapy requires cloning and for this and other reasons such therapy will be a “rich man’s treatment” which creates a very big industry and huge potential profits. That, says Australian medical doctor, bioethicist and lecturer at the University of New South Wales, Dr. Amin Abboud, is the reason for the big push for embryonic stem cell research and cloning.  LifeSiteNews.com interviewed the dynamic, typically Austalian, young doctor at the office of Campaign Life Coalition in Toronto on September 25, while he was on a one day stopover on the way back to Australia from conferences in Europe. Abboud answered questions on bioethics, embryonic stem research and cloning using simple terminology and examples that could be easily followed by almost anyone.  See the rest of this LIFESITENEWS.COM SPECIAL REPORT at:  https://www.lifesitenews.com/ldn/2004/oct/041029a.html